Latest Pharma Insights
J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Scrip - November 28, 2025
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Scrip - November 28, 2025
Sanofi Flies The Flag For France
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
Scrip - November 28, 2025
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
Scrip - November 28, 2025
EU Digital Omnibus Meets MDR And IVDR Revisions: Alignment Or Chaos?
Simultaneous revisions of the EU’s AI, data and medtech rules offer opportunities for simplification and alignment but also risk confusion and competing priorities. With political tensions in the background, does all this portend further unwanted compromises or delays for medtech?
Medtech Insight - November 28, 2025
Simultaneous revisions of the EU’s AI, data and medtech rules offer opportunities for simplification and alignment but also risk confusion and competing priorities. With political tensions in the background, does all this portend further unwanted compromises or delays for medtech?
Medtech Insight - November 28, 2025
Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
Scrip - November 28, 2025
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
Scrip - November 28, 2025
Finance Watch: Lilly Toes The $1 Trillion Valuation Line
Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.
Scrip - November 28, 2025
Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.
Scrip - November 28, 2025
Pipeline Watch: Eight Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 28, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 28, 2025
PAGB Wants 25 Rx-To-OTC Switches Over Next Five Years In The UK
UK consumer healthcare industry association, PAGB, suggests improvements that could help accelerate Rx-to-OTC switch in the country.
HBW Insight - November 28, 2025
UK consumer healthcare industry association, PAGB, suggests improvements that could help accelerate Rx-to-OTC switch in the country.
HBW Insight - November 28, 2025
US Makes First Reformulated Ranitidine Approval Since Withdrawal, Starting With Rx Tablets
In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.
Generics Bulletin - November 28, 2025
In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.
Generics Bulletin - November 28, 2025
Denosumab LOE Looms In Europe As Yet More Approvals Roll In
After the recent onset of European biosimilar competition to aflibercept, the next big biologic LOE on the horizon in Europe is denosumab. Several more approvals have just arrived for rivals to Prolia and Xgeva, setting up a fiercely competitive market once biosimilars launch imminently.
Generics Bulletin - November 28, 2025
After the recent onset of European biosimilar competition to aflibercept, the next big biologic LOE on the horizon in Europe is denosumab. Several more approvals have just arrived for rivals to Prolia and Xgeva, setting up a fiercely competitive market once biosimilars launch imminently.
Generics Bulletin - November 28, 2025
Aeon Secures Funding As FDA Sets New Date For Botox Biosimilar Review
Aeon’s cash infusion and upcoming FDA session, now rescheduled for early next year, positions firm to push ABP-450 biosimilar closer to market entry.
Generics Bulletin - November 28, 2025
Aeon’s cash infusion and upcoming FDA session, now rescheduled for early next year, positions firm to push ABP-450 biosimilar closer to market entry.
Generics Bulletin - November 28, 2025
Long-Awaited EUDAMED Notice Ushers In New Era Of Compliance
After years of delays - and even skepticism in Rome last month when officials hinted at its imminent debut - the long-awaited EUDAMED medical device database release has finally been confirmed
Medtech Insight - November 28, 2025
After years of delays - and even skepticism in Rome last month when officials hinted at its imminent debut - the long-awaited EUDAMED medical device database release has finally been confirmed
Medtech Insight - November 28, 2025
Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Scrip - November 28, 2025
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Scrip - November 28, 2025
J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Scrip - November 28, 2025
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Scrip - November 28, 2025
Sanofi Flies The Flag For France
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
Scrip - November 28, 2025
The Paris-headquartered giant has put the spotlight on its extensive investments at home.
Scrip - November 28, 2025
Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
Scrip - November 28, 2025
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
Scrip - November 28, 2025
Finance Watch: Lilly Toes The $1 Trillion Valuation Line
Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.
Scrip - November 28, 2025
Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.
Scrip - November 28, 2025
Pipeline Watch: Eight Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 28, 2025
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 28, 2025
Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Scrip - November 28, 2025
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Scrip - November 28, 2025
EU Digital Omnibus Meets MDR And IVDR Revisions: Alignment Or Chaos?
Simultaneous revisions of the EU’s AI, data and medtech rules offer opportunities for simplification and alignment but also risk confusion and competing priorities. With political tensions in the background, does all this portend further unwanted compromises or delays for medtech?
Medtech Insight - November 28, 2025
Simultaneous revisions of the EU’s AI, data and medtech rules offer opportunities for simplification and alignment but also risk confusion and competing priorities. With political tensions in the background, does all this portend further unwanted compromises or delays for medtech?
Medtech Insight - November 28, 2025
Long-Awaited EUDAMED Notice Ushers In New Era Of Compliance
After years of delays - and even skepticism in Rome last month when officials hinted at its imminent debut - the long-awaited EUDAMED medical device database release has finally been confirmed
Medtech Insight - November 28, 2025
After years of delays - and even skepticism in Rome last month when officials hinted at its imminent debut - the long-awaited EUDAMED medical device database release has finally been confirmed
Medtech Insight - November 28, 2025
PAGB Wants 25 Rx-To-OTC Switches Over Next Five Years In The UK
UK consumer healthcare industry association, PAGB, suggests improvements that could help accelerate Rx-to-OTC switch in the country.
HBW Insight - November 28, 2025
UK consumer healthcare industry association, PAGB, suggests improvements that could help accelerate Rx-to-OTC switch in the country.
HBW Insight - November 28, 2025
US Makes First Reformulated Ranitidine Approval Since Withdrawal, Starting With Rx Tablets
In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.
Generics Bulletin - November 28, 2025
In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.
Generics Bulletin - November 28, 2025
Denosumab LOE Looms In Europe As Yet More Approvals Roll In
After the recent onset of European biosimilar competition to aflibercept, the next big biologic LOE on the horizon in Europe is denosumab. Several more approvals have just arrived for rivals to Prolia and Xgeva, setting up a fiercely competitive market once biosimilars launch imminently.
Generics Bulletin - November 28, 2025
After the recent onset of European biosimilar competition to aflibercept, the next big biologic LOE on the horizon in Europe is denosumab. Several more approvals have just arrived for rivals to Prolia and Xgeva, setting up a fiercely competitive market once biosimilars launch imminently.
Generics Bulletin - November 28, 2025
Aeon Secures Funding As FDA Sets New Date For Botox Biosimilar Review
Aeon’s cash infusion and upcoming FDA session, now rescheduled for early next year, positions firm to push ABP-450 biosimilar closer to market entry.
Generics Bulletin - November 28, 2025
Aeon’s cash infusion and upcoming FDA session, now rescheduled for early next year, positions firm to push ABP-450 biosimilar closer to market entry.
Generics Bulletin - November 28, 2025
Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics
By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.
In Vivo - November 25, 2025
By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.
In Vivo - November 25, 2025